Suresh Gopi Kalathil
Overview
Explore the profile of Suresh Gopi Kalathil including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
419
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kalathil S, Thanavala Y
Cells
. 2021 Jun;
10(6).
PMID: 34071188
Natural killer (NK) cells account for 25-50% of the total number of hepatic lymphocytes, which implicates that NK cells play an important role in liver immunity. The frequencies of both...
2.
Bhat T, Kalathil S, Bogner P, Lehmann P, Thatcher T, Sime P, et al.
J Immunol
. 2021 Feb;
206(6):1348-1360.
PMID: 33558371
Cigarette smoke is a potent proinflammatory trigger contributing to acute lung injury and the development of chronic lung diseases via mechanisms that include the impairment of inflammation resolution. We have...
3.
Kalathil S, Thanavala Y
Cell Immunol
. 2021 Jan;
361:104280.
PMID: 33445053
Myeloid derived suppressor cells (MDSC) are a heterogenous population of immature myeloid cells that accumulate in tumor bearing host and migrate to lymphoid organs and tumor tissues. This process is...
4.
Bhat T, Kalathil S, Miller A, Thatcher T, Sime P, Thanavala Y
J Immunol
. 2020 Oct;
205(11):3205-3217.
PMID: 33115852
Tobacco smoke exposure is associated with multiple diseases including, respiratory diseases like asthma and chronic obstructive pulmonary disease. Tobacco smoke is a potent inflammatory trigger and is immunosuppressive, contributing to...
5.
Kalathil S, Wang K, Hutson A, Iyer R, Thanavala Y
Oncoimmunology
. 2020 Oct;
9(1):1824863.
PMID: 33101775
The immune modulatory effect of tivozanib, a tyrosine kinase inhibitor, and the underlying immune mechanisms impacting survival of HCC patients have not been investigated. Pre-clinical studies have shown that tivozanib...
6.
Kalathil S, Hutson A, Barbi J, Iyer R, Thanavala Y
JCI Insight
. 2019 Aug;
4(15).
PMID: 31391334
BACKGROUNDSorafenib has been shown to reduce the extent of immunosuppression in patients with hepatocellular carcinoma (HCC). The rationale of this investigation was to identify biomarkers that can predict treatment efficacy...
7.
Bhat T, Kalathil S, Bogner P, Miller A, Lehmann P, Thatcher T, et al.
J Immunol
. 2018 Mar;
200(8):2927-2940.
PMID: 29555783
Despite advocacy to reduce smoking-related diseases, >1 billion people worldwide continue to smoke. Smoking is immunosuppressive and an important etiological factor in the development of several human disorders including respiratory...
8.
Kalathil S, Lugade A, Iyer R, Miller A, Thanavala Y
Oncoimmunology
. 2016 Nov;
5(10):e1226718.
PMID: 27853648
Sorafenib is an oral anti-angiogenic multi-kinase inhibitor used for systemic therapy in patients with advanced hepatocellular carcinoma (HCC) who are not suitable candidates for surgery or liver transplantation. An earlier...
9.
Kalathil S, Lugade A, Miller A, Iyer R, Thanavala Y
JCI Insight
. 2016 Aug;
1(11).
PMID: 27540594
Background: Sorafenib is an oral antiangiogenic agent administered in advanced-stage hepatocellular carcinoma (HCC). Based on preclinical and human studies, we hypothesized that, in addition to its antiangiogenic properties, sorafenib may...
10.
Kalathil S, Thanavala Y
Cancer Immunol Immunother
. 2016 Feb;
65(7):813-9.
PMID: 26910314
A bottleneck for immunotherapy of cancer is the immunosuppressive microenvironment in which the tumor cells are located. Regardless of the fact that large numbers of tumor-specific T cells can be...